Many targets and drugs are being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), a form of non-alcoholic fatty liver disease (NAFLD), but no one really knows which will turn out best for patients.
The NASH Pipeline: Replete With Targets And New Compounds
The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.
More from Alimentary/Metabolic
More from Therapy Areas
At J.P. Morgan, GSK, Sanofi and Pfizer said they are prepared to address questions about vaccines under a new US administration, while former FDA commissioner Gottlieb warned of threats to public safety.
The FDA has approved the IL-23 inhibitor for Crohn's disease to add to its ulcerative colitis approval and put the drug in a position to compete with the likes of AbbVie's Skyrizi and Johnson & Johnson's Stelara.
The Japanese pharma firm has sued a politician claiming defamatory actions on social media around its novel COVID-19 vaccine.